Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Current Liabilities: 2023-2024

Historic Total Current Liabilities for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $10.0 million.

  • Contineum Therapeutics' Total Current Liabilities rose 9.56% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 9.56%. This contributed to the annual value of $10.0 million for FY2024, which is 81.87% up from last year.
  • According to the latest figures from FY2024, Contineum Therapeutics' Total Current Liabilities is $10.0 million, which was up 81.87% from $5.5 million recorded in FY2023.
  • In the past 5 years, Contineum Therapeutics' Total Current Liabilities ranged from a high of $10.0 million in FY2024 and a low of $5.5 million during FY2023.
  • In the last 2 years, Contineum Therapeutics' Total Current Liabilities had a median value of $7.7 million in 2023 and averaged $7.7 million.
  • Data for Contineum Therapeutics' Total Current Liabilities shows a peak YoY surged of 81.87% (in 2024) over the last 5 years.
  • Over the past 2 years, Contineum Therapeutics' Total Current Liabilities (Yearly) stood at $5.5 million in 2023, then soared by 81.87% to $10.0 million in 2024.